£1.4m of contracts for digital health & wearables

RNS Number : 6958B
Cambridge Cognition Holdings PLC
14 June 2021
 

14 June 2021

 

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

 

Cambridge Cognition awarded contracts totalling £1.4m for digital health
and wearable device provision for clinical trials

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a series of contracts from a global pharmaceutical company to provide specialist clinical trial management services.  Under the contracts, the Company will evaluate a range of digital health and wearable devices and supply the devices with associated software and services for four clinical trials, which will assess a drug compound for Central Nervous System ("CNS") disorders.  Cambridge Cognition secured the contracts on the strength of its CNS, digital health, clinical trial and regulatory expertise.

 

The Company has won four contracts for this work, one in late 2020 and three more at this time.  The contracts, expected to generate total revenues of c. £1.4m over two years, are for the supply of software and services as well as the procurement and provision of third-party hardware, which makes up a considerable portion of the total contract value.  As a result of the significant hardware component, the overall margin on the four contracts is lower than the Company would normally generate from a software and services led contract.

 

Pharmaceutical companies are increasingly using digital solutions in virtual or part-virtual clinical trials. Cambridge Cognition meets this evolving demand by providing a full service offering, from gold-standard assessments and specialist consultancy, through to secure data repositories and 24/7 trial support.  In delivering these contracts, Cambridge Cognition will leverage its depth of experience in selecting and supplying devices for CNS clinical trials, meeting regulatory and good clinical practice guidance and providing novel endpoints for pharmaceutical clients. 

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"Cambridge Cognition has earned a reputation for delivering cutting-edge digital health solutions with an infrastructure that meets regulatory demands and satisfies clients' needs for clinical trials.  We were approached for this work, the first of its kind for the Company, on the strength of this reputation.  The result is a new service offering as well as an enhanced relationship with a leading pharmaceutical client."

 

For further information, contact:

 

Cambridge Cognition Holdings Plc

Matthew Stork, Chief Executive Officer

Michael Holton, Chief Financial Officer

Tel: 012 2381 0700

press@camcog.com

finnCap Ltd (NOMAD and Joint Broker)

Geoff Nash / Simon Hicks

Alice Lane / Charlotte Sutcliffe

Tel: 020 7220 0500

(Corporate Finance)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

Tel: 020 3903 7715

 

IFC Advisory Ltd (Financial PR and IR)

Tim Metcalfe / Graham Herring / Zach Cohen

Tel: 020 3934 6630

 

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGPUGGQUPGGAG
UK 100

Latest directors dealings